Cowen to host conference call to discuss third quarter financial results on Friday, October 29. Click here for more information.

Eric Pham, Ph.D

Associate, Research, Cowen Healthcare Investments

Headshot photo of Eric Pham

Dr. Pham joined Cowen Healthcare Investments in November 2019 and focuses on investments into biotechnology companies. Prior to his role at Cowen Healthcare Investments, Dr. Pham was as a Senior Analyst on the investment team at Roivant Sciences, which is a biopharmaceutical company that acquires drugs in development and then establishes NewCos to continue their respective developments. Prior to Roivant, Dr. Pham was a Business Development Consultant at Fannin Innovation Studio, where he evaluated early-stage in-licensing opportunities and supported the operations of select portfolio companies.

Dr. Pham received his Ph.D. in Molecular and Cell Biology from the University of Houston, where his work focused on the role of cytoskeletal proteins in oncology and inflammatory bowel diseases. Prior to graduate school, he was a Research Assistant at the University of California, San Francisco, where he studied the role of the tumor microenvironment in the regulation of receptor tyrosine kinases.

Dr. Pham holds a BA in Molecular and Cell Biology with a focus in Genetics from the University of California, Berkeley.

Get In Touch

Start a conversation with Eric Pham

Investment Management Team

Our team of dedicated investment professionals seek to capitalize on disruption and dislocation across market, geographies and sectors.

View More
Investment management professional reviews report with a client